Improved Tumor Targeting by Combined Use of Two Antitenascin Antibodies

Abstract

The results reported in this study suggest that a monoclonal antitenascin antibody mixture can improve tumor targeting. This strategy could represent progress for therapeutic approaches such as PAGRIT.